Potential Benefits of Herbal Medicine for Schizophrenia: from Empirical Observations to Clinical Trials

Clinical Trials in Psychopharmacology: A Better Brain: Second Edition

Volumn , Issue , 2010, Pages 309-335

  Zhang, Zhang Jin ^a   Tan, Qing Rong ^b   Zhen, Xue Chu ^c   Tong, Yao ^a  

^a THE UNIVERSITY OF HONG KONG   (Hong Kong)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Doctrine of traditional Chinese medicine (TCM) therapeutic effects of formulated herbal preparations being superior; Effectiveness of herbal preparations in treating psychotic symptoms; Free and Easy Wanderer Plus (FEWP, Jia Wei Xiao Yao San in Chinese or Kami Shoyo San in Japanese) for psychiatric conditions; Herbal and antipsychotic agents and interactions in pharmacokinetic or pharmacodynamic mechanism; Herbal preparations in treating antipsychotic induced adverse effects; Individualized treatment strategies, placebo treatment issue in schizophrenic patients; L stepholidine, natural antipsychotic compound; Potential benefits of herbal medicine for schizophrenia empirical observations and clinical trials; Quality controls and toxicological profiles of herbal preparations and herb drug interaction; Strategies for antischizophrenic herbal agents

Indexed keywords

EID: 84886012595     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470749180.ch16     Document Type: Chapter

References (136)

1. Kane, J.M. (1999) Pharmacologic treatment of schizophrenia. Biological Psychiatry, 46, 1396-1408.
2. Elvevag, B. and Goldberg, T.E. (2000) Cognitive impairment in schizophrenia is the core of the disorder. Critical Reviews in Neurobiology, 14, 1-21.
3. Harvey, P.D., Lombardi, J., Leibman, M. et al. (1996) Cognitive impairment and negative symptoms in geriatric chronic schizophrenic patients: a follow-up study. Schizophrenia Research, 22, 223-231.
4. Ayuso-Gutierrez, J.L. and del Rio Vega, J.M. (1997) Factors influencing relapse in the long-term course of schizophrenia. Schizophrenia Research, 28, 199-206.
5. Csernansky, J.G. and Schuchart, E.K. (2002) Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs, 16, 473-484.
6. Beaubrun, G. and Gray, G.E. (2000) A review of herbal medicines for psychiatric disorders. Psychiatric Services, 51, 1130-1134.
7. Sarris, J. (2007) Herbal medicines in the treatment of psychiatric disorders: a systematic review. Phytotherapy Research, 21, 703-716.
8. Wong, A.H., Smith, M., and Boon, H.S. (1998) Herbal remedies in psychiatric practice. Archives of General Psychiatry, 55, 1033-1044.
9. Zhang, Z.J. (2004) Therapeutic effects of herbal extracts and constituents in animal models of psychiatric disorders. Life Sciences, 75, 1659-1699.
10. Rathbone, J., Zhang, L., Zhang, M. et al. (2005) Chinese herbal medicine for schizophrenia. Cochrane Database of Systematic Reviews 19 (Art. No.: CD003444).
11. Rathbone, J., Zhang, L., Zhang, M. et al. (2007) Chinese herbal medicine for schizophrenia: Cochrane systematic review of randomised trials. The British Journal of Psychiatry, 190, 379-384.
12. Bharucha, D.X., Morling, B.A., and Niesenbaum, R.A. (2003) Use and definition of herbal medicines differ by ethnicity. The Annals of Pharmacotherapy, 37, 1409-1413.
13. Silano, M., De Vincenzi, M., De Vincenzi, A. et al. (2004) The new European legislation on traditional herbal medicines: main features and perspectives. Fitoterapia, 75, 107-116.
14. De Smet, P.A. (1997) The role of plant-derived drugs and herbal medicines in healthcare. Drugs, 54, 801-840.
15. De Smet, P.A. and Brouwers, J.R. (1997) Pharmacokinetic evaluation of herbal remedies. Basic introduction, applicability, current status and regulatory needs. Clinical Pharmacokinetics, 32, 427-436.
16. Carlini, E.A. (2003) Plants and the central nervous system. Pharmacology, Biochemistry, and Behavior, 75, 501-512.
17. Houghton, P.J. and Howes, M.J. (2005) Natural products and derivatives affecting neurotransmission relevant to Alzheimer's and Parkinson's disease. Neuro-Signals, 14, 6-22.
18. Houghton, P.J. and Seth, P. (2003) Plants and the central nervous system. Pharmacology Biochemistry and Behavior, 75, 497-499.
19. Chakos, M., Lieberman, J., Hoffman, E. et al. (2001) Effectiveness of secondgeneration antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. The American Journal of Psychiatry, 158, 518-526.
20. Javitt, D.C. (2001) Management of negative symptoms of schizophrenia. Current Psychiatry Reports, 3, 413-417.
21. Peuskens, J., Demily, C., and Thibaut, F. (2005) Treatment of cognitive dysfunction in schizophrenia. Clinical Therapeutics, 27 (Suppl A), S25-S37.
22. Sharma, T. (2002) Impact on cognition of the use of antipsychotics. Current Medical Research and Opinion, 18 (S3), 13-17.
23. Zhu, X.Z., Li, X.Y., and Liu, J. (2004) Recent pharmacological studies on natural products in China. European Journal of Pharmacology, 500, 221-230.
24. Jin, G.Z., Zhu, Z.T., and Fu, Y. (2002) (-)-Stepholidine: a potential novel antipsychotic drug with dual D1 receptor agonist and D2 receptor antagonist actions. Trends in Pharmacological Sciences, 23, 4-7.
25. Chu, H., Jin, G., Friedman, E. et al. (2008) Recent development in studies of tetrahydroprotoberberines: mechanism in antinociception and drug addiction. Cellular and Molecular Neurobiology, 28, 491-499.
26. Mo, J., Guo, Y., Yang, Y.S. et al. (2007) Recent developments in studies of l-stepholidine and its analogs: chemistry, pharmacology and clinical implications. Current Medicinal Chemistry, 14, 2996-3002.
27. Ellenbroek, B.A., Zhang, X.X., and Jin, G.Z. (2006) Effects of (-)stepholidine in animal models for schizophrenia. Acta Pharmacologica Sinica, 27 (9), 1111-1118.
28. Fu, W., Shen, J., Luo, X. et al. (2007) Dopamine D1 receptor agonist and D2 receptor antagonist effects of the natural product (-)-stepholidine: molecular modeling and dynamics simulations. Biophysical Journal, 93, 1431-1441.
29. Gao, M., Liu, C.L., Yang, S. et al. (2007) l-Stepholidine increases the frequency of sEPSC via the activation of D1 dopamine signaling pathway in rat prelimbic cortical neurons. Acta Pharmacologica Sinica, 28, 627-633.
30. Natesan, S., Reckless, G.E., Barlow, K.B. et al. (2008) The antipsychotic potential of l-stepholidine--a naturally occurring dopamine receptor D1 agonist and D2 antagonist. Psychopharmacology (Berlin), 199, 275-289.
31. Mo, Y.Q., Jin, X.L., Chen, Y.T. et al. (2005) Effects of l-stepholidine on forebrain Fos expression: comparison with clozapine and haloperidol. Neuropsychopharmacology, 30, 261-267.
32. Wu, D.C., Shang, Z.M., Fan, L.F. et al. (2005) A double-blind, controlled study of l-stepholidine in treating patients with schizophrenia. Yi Yao Shi Jie (Medicine World), 17, 643-646.
33. Xie, C.G., Xing, X.Z., Wu, D.C. et al. (2002) A double-blind, controlled study of l-stepholidine in treating the negative symptoms of schizophrenic patients. Zhong Guo Shen Jing Ji Bing Za Zhi, 28, 121-122.
34. Xing, X.Z., Xie, C.G., Wu, D.C. et al. (2002) A double-blind, comparative study of l-stepholidine versus clozapine in treating patients with schizophrenia. Shan Dong Jing Shen Yi Xue, 15, 79-80.
35. Sharma, T. and Antonova, L. (2003) Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. The Psychiatric Clinics of North America, 26, 25-40.
36. Sarter, M. and Bruno, J.P. (2004) Developmental origins of the age-related decline in cortical cholinergic function and associated cognitive abilities. Neurobiology of Aging, 25, 1127-1139.
37. Ferreri, F., Agbokou, C., and Gauthier, S. (2006) Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy. Journal of Psychiatry and Neuroscience, 31, 369-376.
38. Friedman, J.I. (2004) Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology (Berlin), 174, 45-53.
39. Wang, R., Yan, H., and Tang, X.C. (2006) Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacologica Sinica, 27, 1-26.
40. Zangara, A. (2003) The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer's disease. Pharmacology, Biochemistry, and Behavior, 75, 675-686.
41. Zhang, Z.J., Tong, Y., Wang, X.Y. et al. (2007) Huperzine A as add-on therapy in patients with treatment-resistant schizophrenia: an open-labeled trial. Schizophrenia Research, 92, 273-275.
42. Atmaca, M., Tezcan, E., Kuloglu, M. et al. (2005) The effect of extract of ginkgo biloba addition to olanzapine on therapeutic effect and antioxidant enzyme levels in patients with schizophrenia. Psychiatry and Clinical Neurosciences, 59, 652-656.
43. Chen, Y.D., He, A.G., Chen, L. et al. (1995) A controlled study of Xing-Shen-He-Ji in treating the negative symptoms of schizophrenic patients. Zhong Guo Min Zhen Yi Xue Za Zhi, 7, 1-3.
44. Cui, J.F., Song, C.S., and Han, W.J. (2008) A control study of Chinese medicinal formulae in combination with clozapine in chronic schizophrenia. Journal of Clinical Psychosomatic Disorder, 14, 317-322.
45. Doruk, A., Uzun, O., and Ozşahin, A. (2008) A placebo-controlled study of extract of ginkgo biloba added to clozapine in patients with treatment-resistant schizophrenia. International Clinical Psychopharmacology, 23, 223-227.
46. Hu, H.Y., Zhu, W.M., and Zhen, G.H. (2007) A clinical controlled study of Mengshi Ditan Decoction combined with western medicine for schizophrenia. Zhong Yi Za Zhi (Journal of Traditional Chinese Medicine), 48, 129-131.
47. Huang, Y.D., Hong, J.B., Yang, Y.L. et al. (1999) A clinical study of Da-Huang-San-Leng Capsule in treating residual symptoms of schizophrenia. Fu Jian Zhong Yi Yao, 30, 1-2.
48. Jia, H.X., Tang, Y.Y., Jiang, Z.K. et al. (2002) Clinical observation of the treatment of cognitive impairment in schizophrenia by the TCM therapy of enforcing spleen and nourishing kidney. Journal of Beijing University of TCM, 27, 80-83.
49. Li, Y.X., Ma, L.Y., Guo, Y.M. et al. (2004) A controlled study of traditional Chinese medicine combined with risperidone in the treatment of first-episode schizophrenia. Shen Jing Jing Shen Wei Sheng, 4, 309-311.
50. Liu, J.L., Ma, L., and Wang, Y. (2007) Clinical observation on effect of modified Daotan Decoction combined with small dose risperidone in treating chronic schizophrenia. Zhongguo Zhong Xi Yi Jie He Za Zhi, 27, 208-210.
51. Luo, H.C., Shen, Y.C., and Meng, F.Q. (1997) Therapeutic effect of shuxuening combining neuroleptics for the treatment of chronic schizophrenia--a double blind study. Zhongguo Zhong Xi Yi Jie He Za Zhi, 17, 139-142.
52. Wen, Y.X., Gan, J.X., Huang, Y.M. et al. (2008) An analysis of the clinical efficacy of Lian-Zi-Qing-Xin-Tang combined with clozapine in schizophrenia. Zhong Guo Min Kang Yi Xue (Medical Journal of Chinese People's Health), 20, 30-31.
53. Wen, Y.X., Huang, Y.M., Gan, J.X. et al. (2007) A controlled study of Ding-Kuang-Zhu-Yu-Tang in first-episode schizophrenia. Guang Xi Yi Xue, 29, 1342-1343.
54. Zhang, X.Y., Zhou, D.F., Zhang, P.Y. et al. (2001) A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. The Journal of Clinical Psychiatry, 62, 878-883.
55. Maciocia, G. (1994) The Practice of Chinese Medicine: The Treatment of Diseases with Acupuncture and Chinese Herbs, Churchill Livingstone, Edinburgh.
56. Ramassamy, C., Longpré, F., and Christen, Y. (2007) Ginkgo biloba extract (EGb 761) in Alzheimer's disease: is there any evidence? Current Alzheimer Research, 4, 253-262.
57. Zhang, X.Y., Zhou, D.F., Su, J.M. et al. (2001) The effect of extract of ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia. Journal of Clinical Psychopharmacology, 21, 85-88.
58. Krausz, M. (2002) Efficacy review of antipsychotics. Current Medical Research and Opinion, 18 (S3), 8-12.
59. Zhang, L. and Han, Y.C. (2005) The use of traditional Chinese medicine to treat amenorrhoea in 50 patients with schizophrenia. Liao Ning Zhong Yi Za Zhi, 32, 930.
60. Yamada, K., Kanba, S., Yagi, G. et al. (1999) Herbal medicine (Shakuyaku-kanzo-to) in the treatment of risperidone-induced amenorrhea. Journal of Clinical Psychopharmacology, 19, 380-381.
61. Ding, G.A., Yu, G.H., Liang, S.C. et al. (2006) Jiawei lingguizhugan tang for obesity induced by psychoactive drugs. Zhong Guo Lin Chuang Kang Fu (Chinese Journal of Clinical Rehabilitation), 10, 46-48.
62. Wang, D.H., Yang, B.S., and Lu, X.P. (2001) The evaluation on the therapeutic efficacy of individualized treatment with TCM in clozapine-induced body gain. Shan Xi Zhong Yi, 17, 18-19.
63. Mou, Y.H. (2008) A clinical observation of Qing-Shen-Yin in treating antipsychotic-induced constipation. Zhong Wai Jian Kang Wen Zhai, 5, 34-35.
64. Zhang, Z.L., Wang, Y., and Wang, X.B. (1995) An observation of the use of Qing-Re-Tang for treating constipation and hypersalivation induced by clozapine in 80 patients with schizophrenia. Shi Yong Zhong Yi Yao Za Zhi, 2, 15.
65. Fan, Q.Z., Zhang, L.Y., Cao, Z.P. et al. (1998) Preventive and therapeutic effects of the herbal formulation called Huang-Yuan-San for diarrhea induced during clozapine treatment (a report of 31 patients). Si Chuan Jing Shen Wei Sheng, 11, 45-46.
66. Yang, B.S. (2006) The use of Wen-Dan-Tang for the treatment of digestive dysfunction induced antipsychotic drugs. Journal of Shanxi College of Traditional Chinese Medicine, 7, 30.
67. Lu, B.L. and Chen, C.P. (2002) Therapeutic effects of An-Shen-Jian-Pi syrup in the treatment of antipsychotic-induced side reactions of digestive tract. Hu Li Xue Za Zhi, 17, 361-363.
68. Li, K.Q., He, X.J., Xu, C.G. et al. (2001) A clinical study on therapeutic effects of An-Shen-Jian-Pi Liquid for antipsychotic-induced digestive dysfunction. Zhong Guo Min Zhen Yi Xue Za Zhi, 13, 326-330.
69. Yi, T.L., Ruan, S.Y., and Lu, H.X. (1999) An observation of Jia-Wei-Suo-Quan-Wan for the treatment of clozapine-induced enuresis in 15 patients with schizophrenia. Zhong Yuan Jing Shen Yi Xue Xue Kan, 5, 223.
70. Chen, X.Z. and Guo, C.Q. (1999) Case studies of Liu-Wei-Di-Huang-Wan used for the treatment of clozapine-induce enuresis (4 cases). Shan Dong Jing Shen Yi Xue, 12, 54.
71. Yuan, H.N., Wang, C.Y., Sze, C.W. et al. (2008) A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia. Journal of Clinical Psychopharmacology, 28, 264-370.
72. Yamada, K., Kanba, S., Murata, T. et al. (1996) Effectiveness of shakuyaku-kanzo-to in neuroleptic-induced hyperprolactinemia: a preliminary report. Psychiatry and Clinical Neurosciences, 50, 341-342.
73. Yamada, K., Kanba, S., Yagi, G. et al. (1997) Effectiveness of herbal medicine (shakuyaku-kanzo-to) for neuroleptic-induced hyperprolactinemia. Journal of Clinical Psychopharmacology, 17, 234-235.
74. Hao, W.D., Lu, X.M., Xu, C.J. et al. (2001) The use of traditional Chinese medicine to treat clozapine-induced hypersalivation. Zhe Jiang Zhong Xi Yi Jie He Za Zhi, 11, 14-15.
75. Huang, W.Z., Ni, Y.X., Li, C.H. et al. (2006) An observation of Ping-Wei-San used for the treatment of clozapine-induced hypersalivation. Zhong Yao Yao Li Yu Lin Chuang, 22, 173-174.
76. Wen, Y.X., Huang, Y.M., Gan, J.X. et al. (2008) A controlled trial of Lian-Zi-Qing-Xin-Tang for clozapine-induced hypersalivation. Zhong Wai Jiang Kang Wen Zhai, 5, 24-25.
77. Fan, Q.Z., Zhang, L.Y., Duan, H. et al. (1996) A controlled study of the herbal formulation called Huang-Yuan-San treating clozapine-induced hypersalivation in 31 patients with schizophrenia. Shan Dong Jing Shen Yi Xue, 9, 17-19.
78. Tang, R.F. (1998) Zuo-Gui-Yin used to treat antipsychotic-induced leucopenia. Hunan Journal of Traditional Chinese Medicine, 1, 28.
79. Kong, M., Gao, X., and Gong, A.H. (2005) A controlled study on the treatment of leukopenia induced by clozapine with modified Dang-Gui-Bu-Xue Decoction. Shan Xi Zhong Yi, 21, 52-53.
80. Lee, J.G., Shin, B.S., Lee, Y.C. et al. (2007) Clinical effectiveness of the Kampo medicine kamishoyosan for adjunctive treatment of tardive dyskinesia in patients with schizophrenia: a 16-week open trial. Psychiatry and Clinical Neurosciences, 61, 509-514.
81. Miyaoka, T., Furuya, M., Yasuda, H. et al. (2008) Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: an open-label study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 32, 761-764.
82. Du, W.J. (1999) The use of Radix Puerariae (Ge-Gen) for the treatment of tardive dyskinesia. Journal of Traditional Chinese Medicine, 40, 134.
83. Marken, P.A., Haykal, R.F., and Fisher, J.N. (1992) Management of psychotropic-induced hyperprolactinemia. Clinical Pharmacology, 11, 851-856.
84. Biller, B.M., Luciano, A., Crosignani, P.G. et al. (1999) Guidelines for the diagnosis and treatment of hyperprolactinemia. The Journal of Reproductive Medicine, 44 (S12), 1075-1084.
85. Perry, G., Nunomura, A., Hirai, K. et al. (2002) Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases? Free Radical Biology and Medicine, 33, 1475-1479.
86. Way, E.L. and Chen, C.F. (1999) Modern clinical applications related to Chinese traditional theories of drug interactions. Perspectives in Biology and Medicine, 42, 512-525.
87. Swerdlow, N.R., Braff, D.L., Taaid, N. et al. (1994) Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Archives of General Psychiatry, 51, 139-154.
88. Swerdlow, N.R., Weber, M., Qu, Y. et al. (2008) Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology (Berlin), 199, 331-388.
89. Dos Santos-Neto, L.L., de Vilhena Toledo, M.A., Medeiros-Souza, P. et al. (2006) The use of herbal medicine in Alzheimer's disease-a systematic review. Evidence-Based Complementary and Alternative Medicine, 3, 441-445.
90. Man, S.C., Durairajan, S.S., Kum, W.F. et al. (2008) Systematic review on the efficacy and safety of herbal medicines for Alzheimer's disease. Journal of Alzheimer's Disease, 14, 209-223.
91. Chen, L.W., Wang, Y.Q., Wei, L.C. et al. (2007) Chinese herbs and herbal extracts for neuroprotection of dopaminergic neurons and potential therapeutic treatment of Parkinson's disease. CNS and Neurological Disorders: Drug Targets, 6, 273-281.
92. Chung, V., Liu, L., Bian, Z. et al. (2006) Efficacy and safety of herbal medicines for idiopathic Parkinson's disease: a systematic review. Movement Disorders, 21, 1709-1715.
93. Li, Q., Zhao, D., and Bezard, E. (2006) Traditional Chinese medicine for Parkinson's disease: a review of Chinese literature. Behavioural Pharmacology, 17, 403-410.
94. Yin, J., Zhang, H., and Ye, J. (2008) Traditional Chinese medicine in treatment of metabolic syndrome. Endocrine, Metabolic and Immune Disorders: Drug Targets, 8, 99-111.
95. Lei, J., Ning, J., and Guo, Z. (1998) Advances in TCM treatment of hyperprolactinemia. Journal of Traditional Chinese Medicine, 18, 230-234.
96. Chen, X., Zhou, H., Liu, Y.B. et al. (2006) Database of traditional Chinese medicine and its application to studies of mechanism and to prescription validation. British Journal of Pharmacology, 149, 1092-1103.
97. Ehrman, T.M., Barlow, D.J., and Hylands, P.J. (2007) chemical databases of Chinese herbal constituents and bioactive plant compounds with known target specificities. Journal of Chemical Information and Modeling, 47, 254-263.
98. Ehrman, T.M., Barlow, D.J., and Hylands, P.J. (2007) Phytochemical informatics of traditional Chinese medicine and therapeutic relevance. Journal of Chemical Information and Modeling, 47, 2316-2334.
99. Ehrman, T.M., Barlow, D.J., and Hylands, P.J. (2007) Virtual screening of Chinese herbs with Random Forest. Journal of Chemical Information and Modeling, 47, 264-278.
100. Paoletta, S., Steventon, G.B., Wildeboer, D. et al. (2008) Screening of herbal constituents for aromatase inhibitory activity. Bioorganic and Medicinal Chemistry, 16, 8466-8470.
101. Do, E.U., Piao, L.Z., Choi, G. et al. (2006) The high throughput screening of neuropeptide FF2 receptor ligands from Korean herbal plant extracts. Peptides, 27, 997-1004.
102. Tian, H., Ip, L., Luo, H. et al. (2007) A high throughput drug screen based on fluorescence resonance energy transfer (FRET) for anticancer activity of compounds from herbal medicine. British Journal of Pharmacology, 150, 321-334.
103. Bensoussan, A., Talley, N.J., Hing, M. et al. (1998) Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. The Journal of the American Medical Association, 280, 1585-1589.
104. Linde, K., Jonas, W.B., Melchart, D. et al. (2001) The methodological quality of randomized controlled trials of homeopathy, herbal medicines and acupuncture. International Journal of Epidemiology, 30, 526-531.
105. Linde, K., ter Riet, G., Hondras, M. et al. (2001) Systematic reviews of complementary therapies-an annotated bibliography. Part 2: herbal medicine. BMC Complementary and Alternative Medicine, 1, 5.
106. Post, R.M. and Luckenbaugh, D.A. (2003) Unique design issues in clinical trials of patients with bipolar affective disorder. Journal of Psychiatric Research, 37, 61-73.
107. Leber, P. (2002) Not in our methods, but in our ignorance. Archives of General Psychiatry, 59, 279-280.
108. Liu, J.P. (2005) Design and application of single case randomized controlled trial. Zhong Guo Zhong Xi Yi Jie He Za Zhi, 25, 252-254.
109. Xu, W.H. (2005) Some thoughts on use of randomized controlled in individual patients in TCM researches. Zhong Guo Lin Chuang Yao Li Xue Yu Zhi Liao Xue, 10, 1315-1317.
110. Wang, H. and Li, J. (2008) A preliminary discussion of two clinical trial designs for phase-II new herbal drugs. Traditional Chinese Drug Research and Clinical Pharmacology, 19, 238-239.
111. Larson, E.B. and Ellsworth, A.J. (1993) An evidence based approach to individualising treatment. The Journal of the American Medical Association, 70, 2708-2712.
112. Zhou, S.F., Xue, C.C., Yu, X.Q. et al. (2007) Metabolic activation of herbal and dietary constituents and its clinical and toxicological implications: an update. Current Drug Metabolism, 8, 526-553.
113. Ushiroyama, T., Ikeda, A., Sakuma, K. et al. (2004) Changes in serum tumor necrosis factor (TNF-alpha) with Kami-Shoyo-San administration in depressed climacteric patients. The American Journal of Chinese Medicine, 32, 621-629.
114. Ishikawa, T., Funahashi, T., and Kudo, J. (2000) Effectiveness of the Kampo Kami-Shoyo-San (TJ-24) for tremor of antipsychotic-induced parkinsonism. Psychiatry and Clinical Neurosciences, 54, 579-582.
115. Yamada, K. and Kanba, S. (2002) Herbal medicine (Kami-Shoyo-San) in the treatment of premenstrual dysphoric disorder. Journal of Clinical Psychopharmacology, 22, 442.
116. Chen, L.C., Tsao, Y.T., Yen, K.Y. et al. (2003) A pilot study comparing the clinical effects of Jia-Wey Shiau-Yau San, a traditional Chinese herbal prescription, and a continuous combined hormone replacement therapy in postmenopausal women with climacteric symptoms. Maturitas, 44, 55-62.
117. Zhang, Z.J., Kang, W.H., Li, Q. et al. (2007) The beneficial effects of the herbal medicine Free and Easy Wanderer Plus (FEWP) for mood disorders: double-blind, placebo-controlled studies. Journal of Psychiatric Research, 41, 828-836.
118. Zhang, Z.J., Kang, W.H., Tan, Q.R. et al. (2007) Adjunctive herbal medicine with carbamazepine for bipolar disorders: a double-blind, randomized, placebo-controlled study. Journal of Psychiatric Research, 41, 360-369.
119. Drasar, P. and Moravcova, J. (2004) Recent advances in analysis of Chinese medical plants and traditional medicines. Journal of Chromatography, B: Analytical Technologies in the Biomedical and Life Sciences, 812, 3-21.
120. Ernst, E. (2004) Risks of herbal medicinal products. Pharmacoepidemiology and Drug Safety, 13, 767-771.
121. Ernst, E. (2002) Toxic heavy metals and undeclared drugs in Asian herbal medicines. Trends in Pharmacological Sciences, 23, 136-139.
122. Barbenel, D.M., Yusufi, B., O'Shea, D. et al. (2000) Mania in a patient receiving testosterone replacement postorchidectomy taking St John's wort and sertraline. Journal of Psychopharmacology, 14, 84-86.
123. Boniel, T. and Dannon, P. (2001) The safety of herbal medicines in the psychiatric practice. Harefuah, 140, 780-783.
124. Bian, Z.X., Moher, D., Dagenais, S. et al. (2006) Improving the quality of randomized controlled trials in Chinese herbal medicine, part II: control group design. Zhong Xi Yi Jie He Xue Bao, 4, 130-136.
125. Kessler, R.C., Soukup, J., Davis, R.B. et al. (2001) The use of complementary and alternative therapies to treat anxiety and depression in the United States. The American Journal of Psychiatry, 158, 289-294.
126. Jang, E.H., Choi, J.Y., Park, C.S. et al. (2005) Effects of green tea extract administration on the pharmacokinetics of clozapine in rats. The Journal of Pharmacy and Pharmacology, 57, 311-316.
127. Shader, R.I. and Greenblatt, D.J. (1985) Phenelzine and the dream machine-ramblings and reflections. Journal of Clinical Psychopharmacology, 5, 65.
128. Jones, B.D. and Runikis, A.M. (1987) Interaction of ginseng with phenelzine. Journal of Clinical Psychopharmacology, 7, 201-202.
129. Deahl, M. (1989) Betel nut-induced extrapyramidal syndrome: an unusual drug interaction. Movement Disorders, 4, 330-332.
130. Dalla Corte, C.L., Fachinetto, R., Colle, D. et al. (2008) Potentially adverse interactions between haloperidol and valerian. Food and Chemical Toxicology, 46, 2369-2375.
131. Fachinetto, R., Villarinho, J.G., Wagner, C. et al. (2007) Valeriana officinalis does not alter the orofacial dyskinesia induced by haloperidol in rats: role of dopamine transporter. Progress in Neuro-psychopharmacology and Biological Psychiatry, 31, 1478-1486.
132. Nair, V., Arjuman, A., Dorababu, P. et al. (2007) Effect of NR-ANX-C (a polyherbal formulation) on haloperidol induced catalepsy in albino mice. The Indian Journal of Medical Research, 126, 480-484.
133. Nair, V., Arjuman, A., Gopalakrishna, H.N. et al. (2008) Withania somnifera root extract on haloperidol-induced catalepsy in albino mice. Phytotherapy Research, 22, 243-246.
134. Fugh-Berman, A. (2000) Herb-drug interactions. Lancet, 355 (9198), 134-138.
135. Yang, X.X., Hu, Z.P., Duan, W. et al. (2006) Drug-herb interactions: eliminating toxicity with hard drug design. Current Pharmaceutical Design, 12, 4649-4664.
136. Bertilsson, L. (2007) Metabolism of antidepressant and neuroleptic drugs by cytochrome p450s: clinical and interethnic aspects. Clinical Pharmacology and Therapeutics, 82, 606-609.